On August 28, 2026, a status update was recorded for a clinical trial involving nesiritide. The study, registered as NCT05928234, is titled "A Comparison of Morbidity Between Patients With Pulmonary Atresia With Intact Ventricular Septum and Uni- or Biventricular Circulation." Its current status is listed as active, not recruiting. No phase designation was provided for this trial in the available record.
The trial is designed to compare morbidity outcomes between patients with pulmonary atresia with intact ventricular septum who have either uni- or biventricular circulation. As the trial is active but not recruiting, enrollment of new participants has closed while the study continues. No results have been posted for this trial as of the date of this update, and no outcome data or findings are included in this brief.
Nesiritide remains classified as an unapproved research compound. This status update reflects only the recruitment and activity status of the registered trial and does not indicate any conclusions about safety or effectiveness. Readers can consult the compound overview for additional background and context on nesiritide.